MacroGenics/$MGNX
1D1W1MYTD1Y5YMAX
Capital at risk
About MacroGenics
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
- Ticker
- $MGNX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 293
- Headquarters
- Rockville, United States
- Website
- www.macrogenics.com
MacroGenics Metrics
BasicAdvanced
$262M
-
-$0.23
1.22
-
Price and volume
Market cap
$262M
Beta
1.22
52-week high
$5.08
52-week low
$1.29
Average daily volume
483K
Financial strength
Current ratio
2.956
Quick ratio
2.918
Long term debt to equity
0.702
Total debt to equity
1.722
Interest coverage (TTM)
-2.25%
Profitability
EBITDA (TTM)
-31.19
Gross margin (TTM)
-0.74%
Net profit margin (TTM)
-8.33%
Operating margin (TTM)
-21.73%
Effective tax rate (TTM)
0.76%
Revenue per employee (TTM)
$600,000
Management effectiveness
Return on assets (TTM)
-8.05%
Return on equity (TTM)
-225.85%
Valuation
Price to revenue (TTM)
1.491
Price to book
12.35
Price to tangible book (TTM)
6.12
Price to free cash flow (TTM)
-3.985
Free cash flow yield (TTM)
-25.10%
Free cash flow per share (TTM)
-1.034
Growth
Revenue change (TTM)
5.83%
Earnings per share change (TTM)
-59.56%
3-year revenue growth (CAGR)
4.73%
10-year revenue growth (CAGR)
5.11%
3-year earnings per share growth (CAGR)
24.69%
10-year earnings per share growth (CAGR)
-13.42%
What the Analysts think about MacroGenics
Analyst ratings (Buy, Hold, Sell) for MacroGenics stock.
Analyst projections of the future price of MacroGenics stock.
MacroGenics Financial Performance
Revenues and expenses
MacroGenics Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing MacroGenics
AllUSDEURGBP
Fund name | Fund size | $MGNX weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.02% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.02% |
iShares Healthcare Innovation£DRDR | £1B | 0.02% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.